07:00 , Mar 25, 2013 |  BC Week In Review  |  Company News

NeuroSearch neurology news

NeuroSearch will cut the majority of its remaining workforce to 3-6 employees as it anticipates completing the transfer of Huntexil pridopidine to Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) by the end...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

NeuroSearch, Teva deal

NeuroSearch sold Teva rights to Huntington's disease compound Huntexil pridopidine for DKK150 million ($26.1 million) up front, plus a potential DKK55 million ($9.6 million) in regulatory and commercial milestones. Teva said it believes Huntexil...
08:00 , Feb 16, 2009 |  BC Week In Review  |  Clinical News

ABT-894: Phase II data

The partners discontinued the development of ABT-894 for diabetic neuropathic pain after 2 parallel, double-blind, international Phase II trials missed the primary endpoints of change in weekly average pain score vs. placebo. The M06-850 trial...
08:00 , Feb 16, 2009 |  BC Week In Review  |  Clinical News

ABT-894: Phase II data

The partners discontinued the development of ABT-894 for diabetic neuropathic pain after 2 parallel, double-blind, international Phase II trials missed the primary endpoints of change in weekly average pain score vs. placebo. The M10-014 trial...
08:00 , Feb 16, 2009 |  BioCentury  |  Finance

Ebb & Flow

Since the beginning of 4Q08, not a single biotech company has filed for an IPO. In that same time frame, eight companies pulled their deals, leaving at least five offerings pending. There were no biotech follow-ons...
02:10 , Feb 12, 2009 |  BC Extra  |  Clinical News

ABT-894 misses diabetic neuropathic pain endpoint

NeuroSearch (CSE:NEUR) and Abbott (NYSE:ABT) discontinued development of ABT-894 for diabetic neuropathic pain after two parallel, double-blind, international Phase II trials missed the primary endpoints of change in weekly average score pain vs. placebo. Last...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Clinical News

ABT-894: Phase II data

In a double-blind, U.S. Phase II trial in about 200 patients, ABT-894 met the primary endpoint of a significant improvement vs. placebo in CAARS-Inv Total Score. The compound also showed comparable efficacy to active control...
07:00 , Jun 23, 2008 |  BioCentury  |  Finance

Ebb & Flow

Having just lost its second most advanced program and with no near-term milestones in sight, Acadia is likely to find itself in the less than optimal position of having to raise money ahead of its...
00:11 , Jun 21, 2008 |  BC Extra  |  Clinical News

ABT-894 meets ADHD endpoint

NeuroSearch (CSE:NEUR) said ABT-894 met the primary endpoint of a significant improvement vs. placebo in Conner's Adult ADHD Rating Scale (CAARS-Inv) Total Score in a U.S. Phase II trial to treat ADHD in adults. The...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Clinical News

ABT-894: Phase II started

ABT began a double-blind, placebo-controlled, dose-ranging Phase II in 275 patients. The product, which ABT has rights to from NEUR, also is in a Phase II trial for attention deficit hyperactivity disorder (ADHD) in adults....